Identity and Access Management Cyber-Security Provider BIO-key’s Q1 Revenue Improved to $1.9M, Driven by 205% Increase in Software License Fees; Investor Call Today at 10am ET
BIO-key International, Inc. (Nasdaq: BKYI) reported Q1 2022 results with revenue at $1.94M, up 3% year-over-year, driven by a 205% growth in software license fees. The company acquired Swivel Secure Europe, adding $368K in revenue in March. Despite a gross profit increase to $1.6M, operating loss widened to $1.0M due to higher expenses from R&D and acquisition costs. The firm maintains a strong outlook, projecting 2022 revenue between $10M and $13M, largely from recurring software licenses, supported by its successful PortalGuard platform and market awards.
- Revenue increased 3% YoY to $1.94M in Q1 2022.
- Software license fees surged 205% YoY, boosting predictability and margins.
- Acquisition of Swivel Secure Europe expanded customer base and revenue potential.
- Gross profit improved to $1.6M due to higher-margin revenue growth.
- Revenue guidance for 2022 projected between $10M and $13M, reflecting potential growth of over 100% from 2021.
- Operating loss increased to $1.0M in Q1 2022 from $0.8M in Q1 2021.
- Total operating expenses rose to $2.6M, outpacing revenue growth.
- Hardware revenue decline impacted overall revenue despite software growth.
WALL, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) and large-scale identity solutions, today reported results for its first quarter ended March 31, 2022 (Q1’22). BIO-key is hosting a conference call today at 10:00 a.m. ET (details below) to review its results and outlook.
BIO-key’s revenue improved
Recent Highlights:
- Expanding PortalGuard Penetration with Local Government Customers, including New Deployments in Missouri, New Mexico, New York, South Dakota and Texas counties and municipalities.
- March 8th acquisition of Swivel Secure Europe, an IAM solutions provider in Europe, the Middle East and Africa (EMEA) that generated approximately
$3.1M in revenue and$578 K in operating income in 2021. contributed$368 K of revenue during the remainder of March, and substantially expands BIO-key’s global customer base, geographic reach, and long term growth potential. - Added New Enterprise Customers and Channel Alliance Program partners
- Initial Hardware Deployments for Nigeria’s National Identity Management Commission’s National ID Enrollment Program in partnership with Sterling Bank Nigeria’s Specta online lending platform - BIO-key’s Pocket10 device for mobile biometric enrollments for agent banking is being deployed to support increased adoption and use of the National Identity Number and mobile banking and payments across the country.
BIO-key CEO Michael DePasquale commented, “As anticipated, we are off to a solid start in Q1’22, with software license sales increasing
“Looking forward, we see an expanding worldwide opportunity to grow our software license revenue base, driven by the compelling security, scalability, ease of use and deployment, and customer value proposition of our PortalGuard IAM platform, along with an expanding array of security solutions. Customers are increasingly recognizing PortalGuard’s, flexibility and differentiated multi-factor authentication capabilities, with support for sixteen different factors including BIO-key’s industry-leading Identity Bound Biometric capabilities.
“PortalGuard continues to gain momentum in the higher education and municipal government verticals and with enterprises as a high-value, easy-to-deploy solution for hybrid access needs. The industry continues to recognize BIO-key as we recently earned four recent 2022 Cybersecurity Excellence Awards and a Security Today magazine 2022 Govies Government Security Award for PortalGuard, in the User Authentication/ Identification/Credentialing and Management category.
Outlook
“There is a clear and growing global need for enterprises of all kinds to protect their data and systems with stronger cybersecurity solutions. BIO-key has built a strong base of products, services and partnerships to address this substantial opportunity. Given the growing momentum in our business, complemented with the addition of Swivel Secure Europe and further progress advancing our opportunities in Africa, we remain confident in achieving our full-year 2022 revenue guidance of
“Our revenue guidance represents growth of more than
Financial Results
Q1’22 revenue increased
Gross profit grew to
Total operating expenses increased to
BIO-key reported an operating loss of
Financial Strength
BIO-key ended the first quarter with working capital of
Conference Call Details | |
Date / Time: | Today, Monday, May 16th at 10 a.m. ET |
Call Dial In #: | 1-877-418-5460 U.S. or 1-412-717-9594 International |
Live Webcast / Replay: | Investor Webcast & Replay – Available for 3 months. |
Audio Replay: | 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 3884798 |
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key has over two decades of expertise in providing authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions, including PortalGuard that provides convenient and secure access to devices, information, applications, and high-value transactions. BIO-key's patented software and hardware solutions, with industry-leading biometric capabilities, enable large-scale on-premises and Identity-as-a-Service (IDaaS) solutions as well as customized enterprise and cloud solutions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of PistolStar and Swivel Secure into our business; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; the duration and extent of continued hostilities in Ukraine and its impact on our European customers, delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Engage with BIO-key | |
Facebook – Corporate: | https://www.facebook.com/BIOkeyInternational/ |
LinkedIn – Corporate: | https://www.linkedin.com/company/bio-key-international |
Twitter – Corporate: | @BIOkeyIntl |
Twitter – Investors: | @BIO_keyIR |
StockTwits: | BIO_keyIR |
Media Contact | Investor Contact |
Erin Knapp | William Jones, David Collins |
Matter Communications | Catalyst IR |
BIO-key@matternow.com | BKYI@catalyst-ir.com |
914-260-3158 | 212-924-9800 |
BIO-key International, Inc. and Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS |
March 31, 2022 | December 31, 2021 | ||||||||||||||
(Unaudited) | |||||||||||||||
ASSETS | |||||||||||||||
Cash and cash equivalents | $ | 5,846,798 | $ | 7,754,046 | |||||||||||
Accounts receivable, net | 2,668,147 | 970,626 | |||||||||||||
Due from factor | 51,850 | 49,500 | |||||||||||||
Note receivable, net of allowance | 82,000 | 82,000 | |||||||||||||
Inventory | 4,956,472 | 4,940,660 | |||||||||||||
Prepaid expenses and other | 363,209 | 216,041 | |||||||||||||
Total current assets | 13,954,691 | 14,012,873 | |||||||||||||
Resalable software license rights | 46,247 | 48,752 | |||||||||||||
Investment – debt security, net | 452,821 | 452,821 | |||||||||||||
Equipment and leasehold improvements, net | 134,929 | 69,168 | |||||||||||||
Capitalized contract costs, net | 279,789 | 249,012 | |||||||||||||
Deposits and other assets | 8,712 | 8,712 | |||||||||||||
Note receivable, net of allowance | 110,000 | 113,000 | |||||||||||||
Operating lease right-of-use assets | 202,513 | 254,100 | |||||||||||||
Intangible assets, net | 2,768,067 | 1,298,077 | |||||||||||||
Goodwill | 1,648,481 | 1,262,526 | |||||||||||||
Total non-current assets | 5,651,559 | 3,756,168 | |||||||||||||
TOTAL ASSETS | $ | 19,606,250 | $ | 17,769,041 | |||||||||||
LIABILITIES | |||||||||||||||
Accounts payable | $ | 1,084,452 | $ | 427,772 | |||||||||||
Accrued liabilities | 896,702 | 828,997 | |||||||||||||
Government loan – Swivel | 580,992 | - | |||||||||||||
Deferred revenue - current | 798,830 | 565,355 | |||||||||||||
Operating lease liabilities, current portion | 156,730 | 177,188 | |||||||||||||
Total current liabilities | 3,517,706 | 1,999,312 | |||||||||||||
Deferred revenue – long term | 54,699 | 67,300 | |||||||||||||
Operating lease liabilities, net of current portion | 54,710 | 86,974 | |||||||||||||
Total non-current liabilities | 109,409 | 154,274 | |||||||||||||
TOTAL LIABILITIES | 3,627,115 | 2,153,586 | |||||||||||||
Commitments and Contingencies | |||||||||||||||
STOCKHOLDERS’ EQUITY | |||||||||||||||
Common stock — authorized, 170,000,000 shares; issued and outstanding; 8,406,451 and 7,853,759 of $.0001 par value at March 31, 2022 and December 31, 2021, respectively | 841 | 786 | |||||||||||||
Additional paid-in capital | 121,509,367 | 120,190,139 | |||||||||||||
Accumulated other comprehensive gain | 43,800 | ||||||||||||||
Accumulated deficit | (105,574,873 | ) | (104,575,470 | ) | |||||||||||
TOTAL STOCKHOLDERS’ EQUITY | 15,979,135 | 15,615,455 | |||||||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 19,606,250 | $ | 17,769,041 |
BIO-key International, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three months ended March 31, | ||||||||
2022 | 2021 | |||||||
Revenues | ||||||||
Services | $ | 395,804 | $ | 380,022 | ||||
License fees | 1,460,183 | 478,958 | ||||||
Hardware | 85,184 | 1,029,658 | ||||||
Total revenues | 1,941,171 | 1,888,638 | ||||||
Costs and other expenses | ||||||||
Cost of services | 210,913 | 175,944 | ||||||
Cost of license fees | 73,230 | 38,969 | ||||||
Cost of hardware | 53,298 | 551,722 | ||||||
Total costs and other expenses | 337,441 | 766,635 | ||||||
Gross Profit | 1,603,730 | 1,122,003 | ||||||
Operating expenses | ||||||||
Selling, general and administrative | 1,797,998 | 1,516,398 | ||||||
Research, development and engineering | 805,266 | 441,651 | ||||||
Total operating expenses | 2,603,264 | 1,958,049 | ||||||
Operating loss | (999,534 | ) | (836,046 | ) | ||||
Other income (expense) | ||||||||
Interest income | 131 | 2,615 | ||||||
Interest expense | - | (18,000 | ) | |||||
Total other income (expense) | 131 | (15,385 | ) | |||||
Net loss | $ | (999,403 | ) | $ | (851,431 | ) | ||
Comprehensive loss: | ||||||||
Net loss | $ | (999,403 | ) | $ | (851,431 | ) | ||
Other comprehensive gain | 43,800 | - | ||||||
Comprehensive loss | $ | (955,603 | ) | $ | (851,431 | ) | ||
Basic and Diluted Loss per Common Share | $ | (0.12 | ) | $ | (0.11 | ) | ||
Weighted Average Shares Outstanding: | ||||||||
Basic and Diluted | 7,885,008 | 7,773,688 |
FAQ
What were BIO-key's Q1 2022 financial results?
What factors drove BIO-key's revenue growth in Q1 2022?
How did the acquisition of Swivel Secure Europe impact BIO-key?
What is BIO-key's revenue guidance for 2022?